Diagnosis value of prostate specific antigen density (PSAD) and prostate specific antigen (PSA) in bone metastases of prostate cancer among Indonesian population by Hendri, Ahmad Zulfan et al.
J Med Sci, Volume 52, Number 2, 2020 April: 138-143
138*corresponding author: syamil117@yahoo.com
Journal of the Medical Sciences
(Berkala Ilmu Kedokteran)
Volume 52, Number 2, 2020;  138-143
http://dx.doi.org/10.19106/JMedSci005202202005
Submited: 2020-02-29
Accepted : 2020-03-29
Keywords: 
prostate cancer;
metastatic prostate cancer;
PSAD;
PSA;
bone metastases;
Diagnosis value of  prostate  specific antigen density 
(PSAD) and prostate specific antigen (PSA) in bone 
metastases of prostate cancer among Indonesian 
population
Ahmad Zulfan Hendri*, Andy Zulfiqqar, Indrawarman Soeharjo, Raden Danarto
Division of Urology, Department of Surgery, Faculty of Medicine, Publik Health, and 
Nursing Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia.
ABSTRACT
Cancer prostate (PCa) is currently reported as the most diagnosed cancer in 
males. Bone metastases in PCa indicate poor prognosis and the major cause of 
pain and death. Early diagnosis of metastases is important in PCa management. 
Prostate specific antigen (PSA) velocity was used to predict overall survival and 
metastasis-free survival. However, this test should be conducted 2 times, for 
at least 4 weeks apart. Therefore, a cross-sectional test with higher positive 
probability value is needed. This study aimed to compare PSA density (PSAD) 
and PSA level to evaluate patients at risk of bone metastases in Yogyakarta, 
Indonesia. Aretrospective study with a total subject of 106 patients with (n 
= 31) and without (n = 75) bone metastases were analyzed. The initial PSA 
measurement, as well as bone scan and prostate volume, were evaluated in all 
patients. Bone survey found to be positive in 31/106 (29.2%) patients. The total 
of 50(47.2%), 10(9.4%) and 46(43.4%) patients had PSA level <50, 50-100 and 
>100ng/mL, respectively. Furthermore, receiver operating characteristic (ROC) 
area under the curve of PSAD (0.75) was higher that that ofPSA (0.65).PSAD 
more than 0.15 indicated sensitivity of 93% and specificity of 38%, while PSA 
more than 20 ng/mL shown sensitivity 82% and specificity 21%. In conclusion, 
PSAD level more than 0.15 shows high sensitivity and specificity in causing 
potential skeletal metastases. Using this PSAD cut-off value, unnecessary 
investigation canbe avoided. 
ABSTRAK
Kanker prostat (PCa) saat ini dilaporkan sebagai kanker yang paling banyak 
didiagnosis pada pria. Metastasis tulang pada PCa menunjukkan prognosis 
yang buruk dan penyebab utama nyeri dan kematian. Diagnosis dini metastasis 
penting dalam manajemen PCa. Kecepatan antigen spesifk prostat (PSA) telah 
digunakan untuk memprediksi kelangsungan hidup secara keseluruhan 
dan kelangsungan hidup bebas metastasis. Namun demikian, tes ini harus 
dilakukan 2 kali, setidaknya selama 4 minggu. Oleh karena itu, tes potong 
lintang dengan nilai probabilitas positif yang lebih tinggi diperlukan. Penelitian 
ini bertujuan untuk membandingkan tingkat PSA density (PSAD) dan PSA untuk 
mengevaluasi pasien yang berisiko metastasis tulang di Yogyakarta, Indonesia. 
Ini merupakan penelitian retrospektif dengan subjek total 106 pasien dengan 
(n = 31) dan tanpa (n = 75) metastasis tulang dianalisis. Pengukuran PSA awal, 
serta pemindaian tulang dan volume prostat, dievaluasi pada semua pasien. 
Survei tulang ditemukan positif pada 31/106 (29,2%) pasien. Total 50(47,2%), 
10(9,4%) dan 46(43,4%) pasienberturut-turutmemilikikadar PSA <50, 50-100, 
dan >100 ng/mL. Selanjutnya, area di bawah kurva ROC menunjukkan kurva 
PSAD (0,75) lebih tinggi dibandingkan PSA (0,65). Nilai PSAD lebih dari 0,15 
mempunyai sensitivitas 93% dan spesifisitas 38%, sementara PSA lebih dari 20 
ng/mL mempunyai sensitivitas 82% dan spesifisitas 21%. Level PSAD lebih dari 
0,15 menunjukkan sensitivitas tinggi dan spesifisitas dalam memperkirakan 
potensi metastasis tulang. Dengan menggunakan nilai ambang batas PSAD ini, 
pemeriksaan yang tidak perlu bias dihindari.
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INTRODUCTION
Prostate cancer (PCa) is well known 
as the most common cancer among men. 
Various biomarkers was introduced over 
the last decades for the early screening 
and surveillance of PCa. Currently, 
prostate specific antigen (PSA) is one of 
the indicators of the bone investigation 
in several guidelines.1,2 The appearance 
of PSA as biomarker screening for early 
diagnosis has shown effectiveness and 
is noted to have reduced more than 
half the morbidity and mortality due 
to early detection. However, the use of 
PSA as indication of bone investigation 
wasassociated with relatively high false 
positive, especially in grey area (PSA 
<20ng/mL) and it has resulted in over-
diagnosis and therapy and affected the 
quality of management of patients.
On current the European Association 
of Urology (EAU) Guidelines, the 
bone investigation is performed in 
symptomatic patients and high PSA level. 
Despite PSA used on monitoring progress 
prostate cancer, the positive finding 
among patients with PSA level between 
20.0 – 49.9 ng/mL is just 16.2%.1This 
indicates that overuse of this modality 
is an issue in bone investigation. The 
overuse remains an issue both in term 
of financial burden and lower quality 
of life patient. Medicare reported the 
bone investigation and downstream 
procedures used at a cost of $ USD 
11,300,000.00- annually and only found 
14% were positive.2 In contrast, late 
staging or under staging resulted in 
standards that caused poor outcomes in 
PCa.
Several options beside PSA have 
been developed such as PSA density 
(PSAD), PSA velocity (PSAV), and PSA 
body mass index (PSABMI) as the 
surveillance indicator in both screening 
and evaluation of PCa. The use of PSA as 
indicator bone metastatic investigation 
may lead to overtreatment and overused 
bone survey. A study reported that PSAD 
is a more powerful predictor of clinical 
stage and prognosis compared to PSA.
However, its role in predicting the bone 
metastatic needs to be evaluated.3 Thus, 
this study as aimed to determine the role 
of PSAD compared to PSA in predicting 
bone metastatic in PCa.
METERIALS AND METHODS
Subjects and data collection 
This study was conducted in Dr. 
Sardjito General Hospital, Yogyakarta, 
Indonesia. Patients were selected from 
the database and medical records. The 
data in this study were collected from 
the medical records with patient’s 
criteriashowing clinical signs and 
symptoms of PCa and confirmed 
histological diagnosis of PCa, bone 
survey, routine PSA measurement.
Prostate volume measurement by USG 
wereenrolled on this study.The data 
was collected from July 2015to January 
2019. Patients who underwent previous 
related surgery, hormonal treatment 
prior to PSA check in Dr.Sardjito General 
Hospital, radiation therapy prior to PSA 
measurement were excluded from this 
study.
Prostate examination
Prostate volume was calculated with 
a TAUS examination. The patient was 
examined with a 3.5 MHz convex probe 
in the supine position. The prostate was 
examined in the sagittal and transverse 
plane; the largest dimensions of the 
prostate in the mid-transverse and mid-
sagittal plane were recorded. Prostate 
measurement was calculated according 
to the ellipsoid shape formula:(Height x 
Length x Width τ/6). PSAD was calculated 
by divided PSA with Prostate volume 
that estimated on the TAUS examination. 
This study received approval from the 
Medical and Health Research Ethic 
Committee, Faculty of Medicine, Public 
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Health and Nursing, Universitas Gadjah 
Mada, Yogyakarta (Ref. KE/0644/05/2019).
Statistical analysis
The cut of value of PSAD determined 
sensitivity, specificity, positive predictive 
values (PPV) and negative predictive 
values (NPV). Statistical analysis was 
performed using SPSS version SPSS 
17.00.
RESULTS
A total of 112 eligible patients were 
enrolled in this study. Only 6 patients 
were excluded due to incomplete data. 
The mean of ages for metastases group 
was 67.62 ± 7.7 years and the non-
metastases group was 69.80± 8.7 years. 
There wasno statistical difference among 
ages between groups. The demographic 
data of this study is shown in TABLE 1.
TABLE 1. Demographic data
Parameters n p
PSA (%)
•	 <50 65
>0.05•	 50-100 22
•	 >100 19
Ages (mean ± SD years) 69.11 9.2
PSA (mean ±SD  ng/mL) 50.80±150
TAUS (mean± SD cm3) 80.4 36.1
Site of bone metastasis
•	 Multiple 7
•	 Pelvis 6
•	 Vertebra thoracic 7
•	 Cranium 1
•	 Pelvis 3
•	 Upper extremities 2
•	 Lower Extremities 4
The mean of non-metastases PSA 
was 43.34± 41.54 ng/mL and metastases 
group was 122.3 ± 122.32 ng/mL.T here 
was statistical difference between two 
groups (p=0.001). The size of prostate 
was56.220.16 cm3 in both groups.
The majority of prostate values in this 
study were less than 50 ng/mL (47.2%), 
with more than 100 ng/mL(43.4%),and 
the between 50-100 ng/mL. The mean of 
ages for metastases was 67.62 7.7 years, 
and none metastasis was 69.80 8.7 years. 
The mean of PSA non-metastases was 
70.94±45.08 ng/mL and prostate size was 
56.2 20.16 cm3.
Bone metastases were the most 
common site of metastases. Bone survey 
was found to be positive in 31 patients 
(29.2%).  The mean of patient’s age was 
69 9 years, from the 31 29.2%. In the 
ROC, area under the curve (AUC) of PSAD 
(0.75) showed higher compared to PSA 
(0.65). PSAD more than 0.15 ng/mL/cm3 
shown sensitivity 93% and specificity 
38% compared to PSA more than 20 g/
mL which shown sensitivity 82 % and 
specificity 21% (FIGURE 1).
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FIGURE 1. Receiver operating characteristic (ROC) curve 
showing sensitivity and specificity of PSA 
(blue line) and PSAD (green line) as diagnosed 
bone-metastasis. PSA: prostate specific antigen, 
PSAD: prostate specific antigen density.
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Positive predictive value (PPV) of 
PSA in predictive bone metastases in 
this study was 93.33 (78.02-98.22%) 
and negative predictive value (NPV) 
was 34.15 (30.16-38.37%). Compared 
to PPV of PSAD, more than 0.15 ng/mL/
cm3 was found as much as 91.67 (78.56 - 
97.08) and NPV as much as 35.53 (30.79 
- 40.56). Although PSAD showed a wider 
AUC than PSA in the prediction of bone 
metastasis, PPV and NPV were observed 
to be comparable.
DISCUSSION
Early detection of metastases 
can reduce harm while maintaining 
the benefits of specific therapy. Bone 
metastases are recorded as the main 
problem in advanced stages of PCa, with 
the most common morbidities were 
caused by severe pain that required 
high doses of anti-analgesia, and 
pathological fractures that resulted in 
spinal compression of spinal problem.4–7 
Bone problems not only resulted from 
metastases itself, but also prostate cancer 
treatment such as androgen deprivation 
therapy (ADT). Pinpoint indication of 
bone investigation is needed to provide 
optimal clinical benefit to patients, and 
cost-effective management of PCa.
Various ways have been sought 
to correlate potential biomarkers of 
skeletal involvement with Gleason 
score >8, PSA >20 ng/mL, and PSAD > 
0.15 ng/mL/cm3.However, many studies 
showed contradictory results that make 
the debate unresolved. The American 
Urological Association (AUA) and 
European Society of Medical Oncology 
(ESMO) recommended to perform bone 
survey or bone scan if PSA valued over 
20 ng/mL8,9 and otherwise guidelines 
recommend that bone investigation 
remain independent from PSA levels.10,11 
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Thus, the role of PSA remains uncertainty 
due lack of sensitivity and specific as 
indicator bone metastases.
With the lack of supporting data, 
PSA remains arbitrary as an indication 
for bone investigation. However, PSA 
remains an irreplaceable biomarker 
for PCa. The current cut-off widely 
used as indication of bone survey was 
PSA level of 20 ng/mL, while PSAD has 
been reported better specificity and 
sensitivity on PCa evaluation.12–16 Our 
study confirms similar results, and the 
data shown PSAD has better area under 
the curve (0.75) compared to PSA (0.65). 
Our study confirmed that using cut 
off point 0.15 ng/mL/cm3 was better 
compared to 20 ng/mL of PSA. On the 
other hand, when the reference point of 
PSA 20 ng/mL was adopted, PSA showed 
better results on positive predictive 
for the bone metastases compared to 
PSAD. However, PSAD shown better on 
excluding bone metastases compared to 
PSA itself. These results indicated that PSA 
is superior as a surveillance tool but can 
cause over diagnoses and unnecessary 
treatment. Both PSA and PSAD may play 
important roles as indication of bone 
investigation, with aforementioned 
pros and cons these modalities still need 
further study on their role. More focused 
studies on patients with PSA less than 20 
ng/mL are needed to establish its role as 
an indication of bone investigation.
The limitation of this study was the 
level of PSA that enrolled in relatively 
considered high risks.Further study on 
patients with PSA lower than 20 ng/mL 
is needed to establish clear protocols for 
usage of PSAD. In addition, in this study 
we used bone survey on evaluating 
bone metastatic, this method may 
results higher false-negative compared 
the standard 99mTc-Bone scan. Even 
though it is too early to conclude that 
the predictive value of PSAD in bone 
metastases, this study indicated that 
PSAD may has potential to minimize 
the overuse of bone survey. The future 
direction of this study is to confirm 
the use of PSAD as indicator of bone 
evaluation and more focusing on lower 
PSA levels.
CONCLUSION
The study shows that using cut off 
point 0.15 ng/mL/cm3of PSAD is better 
compared to 20 ng/mL of PSA.PSA shows 
better results on positive predictive 
for the bone metastases compared to 
PSAD. However, PSAD shows better on 
excluding bone metastases compared to 
PSA itself. 
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